Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

ImageneBio Q3 2026 Results: Net Loss of $15.6M, Loss Narrows

ImageneBio, Inc. (formerly Ikena Oncology) is a clinical-stage biopharmaceutical company focused on developing olevaprubart for immunological and inflammatory indications following its 2025 merger with Legacy Inmagene. As of October 31, 2026, the company had 12,456,281 shares of common stock outstanding and expects to incur significant losses for the foreseeable future while requiring substantial additional funding.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-15.6-24.9
Net income-15.6-24.8
EPS (diluted, $ a share)$-0.91$-2.91

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: IMA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

ImageneBio, Inc.: key numbers

Share price
$3.20Close, Nov 16
Market cap
$39.9M
Shares outstanding
12.46MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from ImageneBio, Inc.

All →
4:18 PM ET 8-K
Financial Results

ImageneBio Financial Results

ImageneBio reported third quarter 2026 financial results, ending the period with $126.6 million in cash and marketable securities. The company highlighted the continued progress of its Phase 2b ADAPTIVE trial for olevaprubart in atopic dermatitis and plans to initiate a Phase 2 study in alopecia areata by year-end 2026.

“We are advancing our trials, developing a robust data set that we believe could demonstrate olevaprubart’s disease-modifying potential and tolerability profile across inflammatory indications. Our safety database continues to grow as we progress, and we are gaining experience across biologic- and JAK-experienced patients as well as those that are naïve to advanced therapies.”

Kristin Yarema, Ph.D., chief executive officer of Imagene

“With ADAPTIVE on course for topline data in the fourth quarter of 2027 and our alopecia areata trial on track to begin by year end, we are executing with capital discipline, and we are poised to deliver data that could demonstrate the true value potential of oleva.”

Kristin Yarema, Ph.D., chief executive officer of Imagene

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.